CRISPR Therapeutics AG (CRSP) Net Equity Issued and Repurchased (2015 - 2026)

CRISPR Therapeutics AG has reported Net Equity Issued and Repurchased for 11 years, with the latest figure at -$722000.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 108.48% year-over-year to -$722000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $447.5 million (up 1471.98% YoY) and the FY2025 annual result came in at $592.2 million, up 96.94% from the prior year.
• Net Equity Issued and Repurchased retreated to -$722000.0 in Q1 2026 per CRSP's latest filing, from $305.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $305.6 million in Q4 2025 and troughed at -$1.0 million in Q2 2024.
• A 5-year average of $71.9 million and a median of $15.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased soared 7145.45% in 2025, then tumbled 108.48% in 2026.
• Over 5 years, Net Equity Issued and Repurchased stood at $970000.0 in 2022, then jumped by 3273.3% to $32.7 million in 2023, then plunged by 54.28% to $15.0 million in 2024, then jumped by 1942.92% to $305.6 million in 2025, then plunged by 100.24% to -$722000.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$722000.0, $305.6 million, and $71.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.